A Phase I Dose Escalation Trial of RO4929097 Administered in Combination With Exemestane in Pre- and Postmenopausal Patients With ER + Metastatic Breast Cancer / A Randomized Phase II Trial Comparing Exemestane in Combination With RO4929097 Compared With Exemestane Alone as Second or Third Line Hormonal Treatment of ER + Metastatic Breast Cancer in Pre- and Post-Menopausal Patients.

Trial Profile

A Phase I Dose Escalation Trial of RO4929097 Administered in Combination With Exemestane in Pre- and Postmenopausal Patients With ER + Metastatic Breast Cancer / A Randomized Phase II Trial Comparing Exemestane in Combination With RO4929097 Compared With Exemestane Alone as Second or Third Line Hormonal Treatment of ER + Metastatic Breast Cancer in Pre- and Post-Menopausal Patients.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 May 2015

At a glance

  • Drugs RG 4733 (Primary) ; Exemestane; Goserelin
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 23 Sep 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 Jun 2013 Planned end date changed from 1 Feb 2012 to 1 Jan 2014 as reported by ClinicalTrials.gov.
    • 14 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top